Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry

Ibragimova, Khava I. E.; Geurts, S.M.E.; Croes, Sander; Erdkamp, Frans; Heijns, Joan B.; Tol, Jolien; Vriens, B.E.P.J.; Aaldering, Kirsten N. A.; Dercksen, M. Wouter; Pepels, M.J.A.E.; Peters, Natascha A. J. B.; Winkel, Linda van de; Tilli, D; Vriens, Ingeborg J. H.; Boer, Maaike de; Tjan‐Heijnen, Vivianne C. G.

doi:10.1007/s10549-021-06178-8

Cited by 8 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a collaborative group from the Netherlands has examined whether the real-world OS improved in patients with HER2-positive advanced BC since the market release of pertuzumab and T-DM1. 25 The SOutheast Netherlands Advanced BREast cancer (SONABRE) registry included 493 systemically treated patients, who had been consecutively diagnosed with HER2-positive metastatic BC between 2008 and 2017. Outcome data confirmed that the survival of patients with HER2-positive advanced BC had significantly improved since the introduction of pertuzumab and T-DM1.…”

Section: Discussionmentioning

confidence: 99%

“…When analyzing OS calculated from second-line starting, independently on the type of first-line OS (months) treatment, patients treated with second-line T-DM1 (325 patients) had a 3-year OS of 40.8%, a 5-year OS of 26.9%, with a median OS of 29 months (95% CI, [23][24][25][26][27][28][29][30][31][32][33][34][35]. Patients treated with second-line lapatinib/capecitabine had a 3-year OS of 39.7% and a 5-year OS of 23.4%, with a median OS of 30 months (95% CI, 24.6-35.4).…”

Section: Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

et al. 2021

View full text Add to dashboard Cite

Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-line pertuzumab-based regimen showed better PFS ( p < 0.0001) and OS ( p = 0.004) than those receiving other treatments. Median PFS and mOS from second-line starting were 8 and 28 months, without significant differences among various regimens. Pertuzumab-pretreated patients showed a mPFS and a mOS from second-line starting not significantly affected by type of second line, that is, T-DM1 or lapatinib/capecitabine ( p = 0.80 and p = 0.45, respectively). Conversely, pertuzumab-naïve patients receiving second-line T-DM1 showed a significantly higher mPFS compared with that of patients treated with lapatinib/capecitabine ( p = 0.004). Median OS from metastatic disease diagnosis was higher in patients treated with trastuzumab-based first line followed by second-line T-DM1 in comparison to pertuzumab-based first-line and second-line T-DM1 ( p = 0.003), although these data might be partially influenced by more favorable prognostic characteristics of patients in the pre-pertuzumab era. No significant differences emerged when comparing patients treated with ‘old’ or ‘new’ drugs ( p = 0.43), even though differences in the length of the follow-up between the two cohorts should be taken into account. Conclusion: Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Characteristicsmentioning

confidence: 99%

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Including different hospital types is considered a strength of this study. Nowadays, the PFS and OS are expected to be longer as reported in this study since an underuse of pertuzumab was observed in 2013 and 2014, whereas pertuzumab use was stable in 2015–2017 [ 8 ]. The OS is also expected to further increase due to new HER2-targeted treatment options [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…To present the use of systemic therapy, we reported first-given treatment regimens (HER2-targeted therapy, chemotherapy and/or endocrine therapy) and the use of systemic agents within the first five years from diagnosis (any HER2-targeted therapy, pertuzumab and T-DM1) per period using competing risk methodology [ 8 ]. Use of locoregional therapy (surgery of the primary tumour, and surgery and radiotherapy of a metastatic site) within the first year after diagnosis was determined per time period using competing risk methodology.…”

Section: Methodsmentioning

confidence: 99%

“…As of 2022, trastuzumab-deruxtecan (T-DXD) and a combination of capecitabine, trastuzumab and tucatinib have been added to the treatment landscape of patients with HER2 + advanced breast cancer (ABC) [ 5 ]. Both the French ESME and Dutch SONABRE real-world registries have shown an improvement in the overall survival of patients with HER2 + metastatic breast cancer (including both de novo and metachronous metastases) since the introduction of pertuzumab and T-DM1 [ 7 , 8 ]. The time trends in progression-free and overall survival in patients with de novo HER2+ ABC in specific have not been reported so far.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

Geurts,

Ibragimova,

Ding

et al. 2024

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Purpose The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer (ABC) has improved since the introduction of pertuzumab in 2013. In addition to PFS, we aimed to determine differences in overall survival (OS) and the use of systemic and locoregional therapies. Methods Included were patients systemically treated for de novo HER2+ ABC in ten hospitals in 2008–2017 from the SONABRE Registry (NCT-03577197). First-line PFS and OS in 2013–2017 versus 2008–2012 was determined using Kaplan–Meier analyses and multivariable Cox proportional hazards modelling. First-given systemic therapy and the use of locoregional therapy within the first year following diagnosis were determined per period of diagnosis. Results Median and five-year PFS were 26.6 months and 24% in 2013–2017 (n = 85) versus 14.5 months and 10% in 2008–2012 (n = 81) (adjusted HR = 0.65, 95%CI:0.45–0.94). Median and five-year OS were 61.2 months and 51% in 2013–2017 versus 26.1 months and 28% in 2008–2012 (adjusted HR = 0.55, 95%CI:0.37–0.81). Of patients diagnosed in 2013–2017 versus 2008–2012, 84% versus 60% received HER2-targeted therapy and 59% versus 0% pertuzumab-based therapy as first-given therapy. Respectively, 27% and 23% of patients underwent locoregional breast surgery, and 6% and 7% surgery of a metastatic site during the first year following diagnosis. Conclusion The prognosis of patients with de novo HER2 + ABC has improved considerably. Since 2013 one in four patients were alive and free from progression on first-given therapy for at least five years.

show abstract

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

Ibragimova

Geurts

Meegdes

et al. 2023

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of systemic therapy and by hormone receptor (HR) status. Methods We identified 330 patients diagnosed with HER2 + ABC in 2013–2018 in the Southeast of The Netherlands, of whom 64% with HR + /HER2 + and 36% with HR-/HER2 + disease. Overall survival (OS) from start of therapy was calculated using the Kaplan–Meier method. Results In real world, 95% of patients with HR + /HER2 + and 74% of patients with HR-/HER2 + disease received systemic therapy. In HR + /HER2 + disease, use of endocrine, chemo- and HER2-targeted therapy was , respectively, 64%, 46% and 60% in first line, and 39%, 64% and 75% in fourth line. In HR-/HER2 + disease, 91–96% of patients received chemotherapy and 77–91% HER2-targeted therapy, irrespective of line of therapy. In patients with HR + /HER2 + disease, median OS was 34.9 months (95%CI:25.8–44.0) for the first line and 12.8 months (95%CI:10.7–14.9) for the fourth line. In HR-/HER2 + disease, median OS was 39.9 months (95%CI:23.9–55.8) for the first line and 15.2 months (95%CI:10.9–19.5) for the fourth line. For patients treated with first-line pertuzumab, trastuzumab plus chemotherapy, median OS was not reached at 56.0 months in HR + /HER2 + disease and 48.4 months (95%CI:32.6–64.3) in HR-/HER2 + disease. Conclusion Survival times for later lines of therapy are surprisingly long and justify the use of multiple lines of systemic therapy in well-selected patients with HER2 + ABC. Our real-world evidence adds valuable observations to the accumulating evidence that within HER2 + ABC, the HR status defines two distinct disease subtypes.

show abstract

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry

Cited by 8 publications

References 31 publications

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

Contact Info

Product

Resources

About